The deal, which brings Nestle’s total investment to $273 million, raises Nestle’s stake in the drug developer to about 19 percent from 14.5 percent. The two companies also extended their two-year pact to develop therapies for food allergies by two years.
In the U.S. there is no approved treatment for peanut allergies, so drugmakers see a huge opportunity in the market.
Read the full report here.
More articles on pharmacy:
Walgreens managers lose thousands in bonuses: 3 things to know
14 pharma companies post Q3 profits over $1B
Neulasta biosimilar will get $4,175 price tag
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
